Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fedratinib - Celgene Corporation

Drug Profile

Fedratinib - Celgene Corporation

Alternative Names: FEDR; INREBIC; Inrebic; SAR-302503; TG-101348

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TargeGen
  • Developer Bristol-Myers Squibb; Celgene Corporation; Sanofi
  • Class Antifibrotics; Antihaemorrhagics; Antineoplastics; Phenyl ethers; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myelofibrosis
  • Discontinued Essential thrombocythaemia; Polycythaemia vera; Solid tumours

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy, Treatment-experienced) in Australia (PO, Capsule)
  • 10 Dec 2023 Interim efficacy and adverse events data from the phase-III FREEDOM2 trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top